Verrica Pharmaceuticals (VRCA) EBITDA Margin (2021 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly EBITDA Margin of 193.41% for Q1 2026, up 4300.0% year-over-year from 4.4% in Q1 2025, and down 36.94% quarter-over-quarter from 141.24% in Q4 2025.
Verrica Pharmaceuticals (VRCA) EBITDA Margin (2021 - 2026) Analysis & Trends
Verrica Pharmaceuticals' EBITDA Margin history runs 6 years deep, the most recent figure standing at 193.41% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 4300.0% year-over-year to 193.41%; the TTM figure through Mar 2026 stood at 37.05% (up 47919.0% YoY), while the FY2025 annual figure was 34.25%, up 83700.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 193.41%, down from 141.24% in the prior quarter.
- The five-year high for EBITDA Margin was 17.41% in Q3 2022, with the low at 19159.46% in Q1 2023.
- The 5-year median for EBITDA Margin is 819.92% (2023), against an average of 2848.85%.
- The sharpest annual moves came in 2023 and 2024: EBITDA Margin sank 1744020 bps in 2023, then soared 1867334 bps in 2024.
- Verrica Pharmaceuticals' EBITDA Margin stood at 9133.82% in 2022, then surged by 87 bps to 1163.78% in 2023, then plunged by 185 bps to 3316.86% in 2024, then surged by 96 bps to 141.24% in 2025, then tumbled by 37 bps to 193.41% in 2026.
- Business Quant data shows VRCA's EBITDA Margin at 193.41% in Q1 2026, 141.24% in Q4 2025, and 11.34% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.75% |
| 10 | Verrica Pharmaceuticals | 101.84 Mn | 90.64 Mn | - | -223.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -223.42% |
| Mar 31, 2026 | -193.41% |
| Dec 31, 2025 | -141.24% |
| Sep 30, 2025 | 11.34% |
| Jun 30, 2025 | 11.89% |
| Mar 31, 2025 | -236.41% |
| Dec 31, 2024 | -3,316.86% |
| Sep 30, 2024 | -1,162.49% |
| Jun 30, 2024 | -293.72% |
| Mar 31, 2024 | -486.12% |
| Dec 31, 2023 | -1,163.78% |
| Sep 30, 2023 | -819.92% |
| Jun 30, 2023 | -6,382.42% |
| Mar 31, 2023 | -19,159.46% |
| Dec 31, 2022 | -9,133.82% |
| Sep 30, 2022 | 17.41% |
| Jun 30, 2022 | -4,262.15% |
| Mar 31, 2022 | -1,719.26% |
| Mar 31, 2021 | 0.50% |